These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 29446129)

  • 1. Editorial: infliximab trough levels and histological healing in ulcerative colitis-a step towards personalised biologic therapy.
    Lobaton T; De Vos M
    Aliment Pharmacol Ther; 2018 Mar; 47(6):855-856. PubMed ID: 29446129
    [No Abstract]   [Full Text] [Related]  

  • 2. Histological healing after infliximab induction therapy in children with ulcerative colitis.
    Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
    World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab.
    Magro F; Lopes SI; Lopes J; Portela F; Cotter J; Lopes S; Moreira MJ; Lago P; Peixe P; Albuquerque A; Rodrigues S; Silva MR; Monteiro P; Lopes C; Monteiro L; Macedo G; Veloso L; Camila C; Afonso J; Geboes K; Carneiro F;
    J Crohns Colitis; 2016 Dec; 10(12):1407-1416. PubMed ID: 27226417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
    Farkas K; Rutka M; Golovics PA; Végh Z; Lovász BD; Nyári T; Gecse KB; Kolar M; Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Malickova K; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Palatka K; Lakatos PL; Lukas M; Molnár T
    J Crohns Colitis; 2016 Nov; 10(11):1273-1278. PubMed ID: 27106537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.
    Seow CH; Newman A; Irwin SP; Steinhart AH; Silverberg MS; Greenberg GR
    Gut; 2010 Jan; 59(1):49-54. PubMed ID: 19651627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.
    Bálint A; Rutka M; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Szepes Z; Nagy F; Palatka K; Lovas S; Végh Z; Kürti Z; Csontos Á; Miheller P; Nyári T; Bor R; Milassin Á; Fábián A; Szántó K; Lakatos PL; Molnár T; Farkas K
    Expert Opin Biol Ther; 2018 Nov; 18(11):1181-1187. PubMed ID: 30277084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
    Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients.
    Pérez-Pitarch A; Ferriols-Lisart R; Alós-Almiñana M; Mínguez-Pérez M
    Rev Esp Enferm Dig; 2015 Mar; 107(3):137-42. PubMed ID: 25733037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse gastroduodenitis associated with ulcerative colitis: treatment by infliximab.
    Chiba M; Ono I; Wakamatsu H; Wada I; Suzuki K
    Dig Endosc; 2013 Nov; 25(6):622-5. PubMed ID: 24164601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ulcerative colitis endoscopic index of severity is associated with long-term prognosis in ulcerative colitis patients treated with infliximab.
    Saigusa K; Matsuoka K; Sugimoto S; Arai M; Kiyohara H; Takeshita K; Mizuno S; Mori K; Nanki K; Takeshita T; Nakazato Y; Yajima T; Naganuma M; Hisamatsu T; Ogata H; Iwao Y; Kanai T
    Dig Endosc; 2016 Sep; 28(6):665-70. PubMed ID: 26997640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis.
    Yang Z; Wu Q; Wu K; Fan D
    Aliment Pharmacol Ther; 2010 Feb; 31(4):486-92. PubMed ID: 19925496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
    Kobayashi T; Suzuki Y; Motoya S; Hirai F; Ogata H; Ito H; Sato N; Ozaki K; Watanabe M; Hibi T
    J Gastroenterol; 2016 Mar; 51(3):241-51. PubMed ID: 26162647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab-associated alveolitis after treatment for severe left-sided ulcerative colitis.
    Veerappan SG; O'Morain CA
    Eur J Gastroenterol Hepatol; 2009 Jul; 21(7):830-2. PubMed ID: 19398919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
    Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
    Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison.
    Motaghi E; Ghasemi-Pirbaluti M; Zabihi M
    Pharmacol Res; 2019 Jan; 139():120-125. PubMed ID: 30395950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
    Yamamoto-Furusho JK; Uzcanga LF
    Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease.
    Bodini G; Giannini EG; Savarino V; Del Nero L; Lo Pumo S; Brunacci M; De Bortoli N; Jain A; Tolone S; Savarino E
    Dig Liver Dis; 2018 May; 50(5):452-456. PubMed ID: 29274766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-α antibodies in ulcerative colitis.
    Morita Y; Bamba S; Takahashi K; Imaeda H; Nishida A; Inatomi O; Sasaki M; Tsujikawa T; Sugimoto M; Andoh A
    Scand J Gastroenterol; 2016 Aug; 51(8):934-41. PubMed ID: 26888161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
    Pouillon L; Van Stappen J; Bossuyt P; Danese S; Peyrin-Biroulet L
    Best Pract Res Clin Gastroenterol; 2018; 32-33():17-25. PubMed ID: 30060934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
    Hendy P; Hart A
    Aliment Pharmacol Ther; 2015 Jan; 41(1):149. PubMed ID: 25483435
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.